BeyondSpring Inc.
BeyondSpring Inc. develops innovative cancer therapies, with its lead asset Plinabulin, a novel microtubule modulator in clinical trials for non-small cell lung cancer and chemotherapy-induced neutropenia prevention.
BeyondSpring Inc is a Healthcare company operating in Biotechnology with a $66.2M market cap.
Most recent reported earnings: Q1 FY2026 (May 5, 2026).
3 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Spoken Alpha tracks BYSI's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 6/10 quarters with 70% positive reaction rate
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BYSI.
$ curl https://api.spokenalpha.com/v1/companies/BYSIFAQ
Spoken Alpha indexes BYSI's earnings call transcripts at https://spokenalpha.com/companies/BYSI. Each call links to attributed speakers and parsed analyst Q&A. BeyondSpring Inc.'s own investor relations page is at https://beyondspringpharma.com/investors/.
BeyondSpring Inc. (BYSI) held its most recent earnings call on 2022-04-14, covering fiscal Q4 2021.
BeyondSpring Inc. (BYSI) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-05 | $-0.05 | $0.00 | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.05 | — | — | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-12 | $-0.04 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-04-29 | $-0.06 | $1.02 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-26 | $0.00 | $0.92 | -100.0% | $-1.0M | — | — | EODHD |
| Q2 FY2024 | 2024-08-28 | $-0.19 | $0.80 | -100.0% | $500.0K | — | — | EODHD |
| Q1 FY2024 | 2024-04-30 | $0.00 | $-0.82 | +100.0% | $500.0K | — | — | EODHD |
| Q3 FY2023 | 2023-12-20 | $0.00 | $-0.80 | +100.0% | $438.0K | — | — | EODHD |
| Q2 FY2023 | 2023-07-09 | $0.00 | $-0.75 | +100.0% | — | — | — | EODHD |
| Q1 FY2023 | 2023-04-17 | $-0.58 | $-0.28 | -100.0% | $437.5K | — | — | EODHD |
| Q4 FY2022 | 2022-12-30 | — | $-0.58 | — | $338.0K | — | — | EODHD |
| Q3 FY2022 | 2022-12-21 | $-0.44 | $-0.44 | 0.0% | $337.5K | — | — | EODHD |
| Q2 FY2022 | 2022-09-08 | $-0.47 | $-0.24 | -95.8% | — | — | — | EODHD |
| Q4 FY2021 | 2022-04-13 | $-0.24 | $-0.26 | +7.7% | $338.0K | — | — | EODHD |
| Q3 FY2021 | 2021-12-29 | $-0.47 | $-0.37 | -27.0% | $337.0K | — | — | EODHD |
| Q2 FY2021 | 2021-09-09 | $-0.49 | $-0.33 | -48.5% | $338.0K | — | — | EODHD |
| Q1 FY2021 | 2021-04-29 | $-0.52 | $-0.45 | -15.6% | $338.0K | — | — | EODHD |
| Q4 FY2020 | 2020-12-30 | $-0.52 | $-0.45 | -15.6% | $180.0K | — | — | EODHD |
| Q3 FY2020 | 2020-11-16 | $-0.48 | $-0.54 | +11.1% | $0 | — | — | EODHD |
| Q2 FY2020 | 2020-09-02 | $-0.46 | $-0.57 | +19.3% | $0 | — | — | EODHD |
Source: EODHD. BYSI reported actuals as published; sparse fields render as —.
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2021 | $2.68 | $2.47 | +8.3% | +1.9% | +0.4% |
| Q4 FY2021 | $2.61 | $2.66 | -1.8% | -5.1% | -7.9% |
| Q3 FY2021 | $2.80 | $2.66 | +5.3% | -1.6% | -0.8% |
| Q2 FY2021 | $2.81 | $2.75 | +2.2% | -0.1% | +0.5% |
| Q1 FY2020 | $2.73 | $2.74 | -0.2% | +0.2% | -1.9% |
OTHER_C_SUITE since 2024 • 1/2 beats (50%) • last call held guidance Q1 FY2021
| Q4 FY2020 |
| $2.68 |
| $2.77 |
| -3.3% |
| +2.6% |
| +0.6% |
| Q3 FY2020 | $2.67 | $2.64 | +1.1% | +4.6% | +6.4% |
| Q2 FY2020 | $2.96 | $2.74 | +8.0% | +1.9% | -0.8% |
| Q1 FY2019 | $2.73 | $2.81 | -2.8% | +4.5% | +6.2% |
| Q4 FY2019 | $2.71 | $2.68 | +1.0% | +2.4% | +1.1% |